Shots:

• Exelixis to acquire GamaMabs' AMHR2 Ab technology for $5M and additionally payment upon achieving certain milestones. Following the closing of the transaction- Exelixis will control GamaMabs’ AMHR2 franchise technology including all assets related to murlentamab (GM-102)
• The preclinical data support the potential of AMHR2 for novel oncology therapies and demonstrated the safety of an anti-AMHR2 mAbs in human clinical trials
• Exelixis expands its biotherapeutics portfolio by integrating its ADC capabilities to GamaMabs’ Abs against AMHR2 and helps to provide rapid and effective development of cancer therapies

  Ref: BUSINESS WIRE | Image: Exelixis